In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical result of social, economic and health system growth worldwide. Vaccination and infectious diseases control, changing dietary habits worldwide, sedentary behaviour, globalisation, industrialisation (resulting in a shift from manual to sedentary labour), tobacco and sugary beverage surges in low-and middle-income countries and rapid urbanisation have all played a role in this epidemic transition. At the same time, the increase in cardiovascular risk factors, together with a decline in mortality in high-income countries in the past two decades, has led to a significant upsurge in the prevalence of secondary prevention of ischaemic heart disease. With this, the effect that non-adherence to cardioprotective drugs is having has become progressively clear, both in terms of clinical outcomes and as a driver of increased healthcare expenditure. The cardiovascular polypill, which was originally proposed as a strategy to improve accessibility to cardioprotective drugs worldwide, has proven to be a mainstay therapeutic approach for improving medication adherence in cardiovascular disease. In the current paper, we aim to review the need for a polypill strategy in the present scenario of cardiovascular disease, the available data that support such a strategy and the various clinical trials that are in progress that will help further shape future indications for the cardiovascular polypill.
Introduction
Demographic and societal changes such as an ageing population, globalisation, rapid urbanisation and population growth worldwide have had profound effects on global disease patterns. As a result, noncommunicable diseases (NCDs) have overtaken communicable diseases as the world's major disease burden. NCDs, including cardiovascular disease (CVD), cancer, chronic obstructive pulmonary disease and diabetes mellitus, are the dominant public health challenges of the 21st century. CVD has become the leading cause of death worldwide, accounting for 17.3 million deaths per year, a number that is expected to grow to 23.6 million by 2030. 1 Progressively, the populations affected are those in low-and middle-income countries (LMICs), where a staggering 80% of total CVD deaths occur, typically at younger ages than in higher-income countries, and where the human and financial resources to address this condition are most inadequate. 2 In addition to lifestyle interventions in order to mediate modifiable risk factors, cardioprotective medications are integral to CVD control strategies. Furthermore, optimising modifiable risk factors through a total risk management approach (i.e. not treating single risk factors in isolation) has been shown to be a more effective way of preventing the recurrence of CVD. 3 Despite the large evidence base for medicines to prevent and treat CVD, there is a wide gap between indication and realworld use of cardioprotective drugs. The reasons for this are complex and include a wide variability in the pattern of prescription among physicians, limited access to expensive drugs in emerging countries and poor adherence to medication. The cardiovascular polypill was proposed by the World Health Organization (WHO) more than a decade ago as a 'best buy' intervention for secondary prevention, as a simple, cost-effective public health strategy to reduce the evidence implementation gap and as a vehicle to improve the prescription, accessibility, adherence and cost of secondary CVD prevention ( Figure 1 ).
Accessibility to cardioprotective drugs in LMICs: a major public health challenge Two major large, multinational studies have addressed the issue of accessibility to secondary prevention therapies for CVD predominantly in urban and rural areas of LMICs. The WHO Prevention of Recurrences of Myocardial Infarction and Stroke (PREMISE) study analysed whether patients received the indicated therapy. 4 The authors found that in 10 LMICs, the proportion of patients with CVD who had received medications was low for angiotensin-converting .enzyme inhibitors (ACEIs; 40% for coronary heart disease and 38% for stroke), b-blockers (48% for coronary heart disease) and statins (30% for coronary heart disease and 14% for stroke). The Prospective Urban Rural Epidemiology (PURE) study analysed the use of five therapeutic classes in 17 LMICs among patients with known CVD. Only a quarter of CVD patients (25%) reported receiving antiplatelet drugs, 17% received b-blockers, 20% received ACEIs or angiotensin receptor blockers and 15% received statins. 5 The lack of accessibility to secondary prevention therapies shown by these studies highlights the dimensions of the NCD global challenge in the 21st century, which shows remarkable similarities to the surge of the antiretroviral polypill in order to contain the HIV pandemic nearly two decades ago. In September 2011, the United Nations General Assembly (UNGA) held for the first time a High-Level Meeting on the prevention and control of NCDs. It was only the second time in history that the UNGA had summoned a High-Level Meeting in response to a global health crisis. The first took place in 2000 and primarily addressed the HIV/ AIDS epidemic, and was followed by an unprecedented global response. In 2002, the antiretroviral polypill emerged as a solution in order to facilitate the prescription, accessibility and adherence and to limit the increasing costs associated with multidrug regimens, and it is currently a mainstay in the control of major communicable diseases such as tuberculosis, HIV/ AIDS and malaria. 6 As a consequence, HIV is increasingly becoming a chronic disease in parts of the world where it used to carry vast mortality and morbidity rates. The first cardiovascular polypill for secondary prevention, containing aspirin, ramipril and a statin, was approved by the European Medicines Agency (EMA) in 2014, 8 is currently approved in 48 counties, and is commercially available in Europe and Latin America, so why has the successful experience of the communicable disease polypills not helped to pave the way in NCDs? First, the chronicity inherent in NCDs has limited its priority in the political agenda, as they lack the urgency, fear of contagion and sense of injustice associated with HIV/AIDS. Second, in many regions of the world, NCDs coexist with communicable diseases as leading public health concerns (the so-called 'double burden of disease'), and while governments have put into place policies to tackle communicable diseases, NCDs are not perceived as imminent public health threats. Third, NCDs lack the media attention and celebrity support that was the mainstay of the HIV/ AIDS mobilisation. Fourth, there is an inherent negative perception of the polypill due to the original proposal as a 'vaccination strategy' that has carried over to the accepted and approved secondary prevention indication. Wald and Law's original 2003 vaccination strategy focused on the use of a polypill composed of a statin, three blood pressure (BP) medications each at half standard dose, folic acid and aspirin, and it would reduce ischaemic heart disease events by 88% and strokes by 80%, if taken by everyone over the age of 55 years (regardless of risk profile) and everyone with existing CVD. Table 1 summarises some of the advantages of a polypill strategy and the barriers that impede worldwide implementation.
The current landscape of cardiovascular morbidity and mortality, together with the projections of its devastating effects, especially in LMICs, call for an urgent reconciliation with the polypill concept for all stakeholders in order to overcome the critical barriers that prevent the implementation of a major public health action item for the global CVD community.
Parallel to the surge of CVD in LMICs, mortality from coronary heart disease has been decreasing in high-income countries because of a combination of lifestyle changes, better risk factor control, improved management of acute coronary syndromes and improved prescription of secondary prevention medications, which has led to a significant increase in the secondary prevention population. When accessibility to treatment and the prescription of cardioprotective medication targets are met, a new barrier to effective secondary prevention arises: the complex phenomenon of nonadherence to medications ( Figure 2 ).
Despite the established efficacy of cardiovascular medications, adherence in patients taking these medications for both the primary and secondary prevention of CVD was estimated at only 57% in a recent meta-analysis of almost 400,000 patients. 10 Suboptimal adherence reduces the effectiveness of these essential medications and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. 11 The impact of non-adherence is monumental both in terms of clinical outcomes and as a driver of 12 Using pharmacy claims in order to calculate the proportion of days covered (PDC) for statins and ACEIs, patients were stratified by PDC as fully adherent (80%), partially adherent (40-79%) or nonadherent (<40%). Incidence functions and rates of hospitalisations between groups were compared. In the post-MI cohort, which included 4015 adults who initiated both statins and ACEI medications, only 43% of patients were classified as fully adherent, 31% were classified as partially adherent and 26% were classified as non-adherent. The findings showed that acute post-MI patients must maintain a very high level of adherence (greater than 80%) in order to accrue the benefit -prevention of a secondary cardiovascular event. Fully adherent patients were at a significantly lower risk of major adverse cardiovascular events than partially adherent (a 19% risk reduction) and non-adherent populations (a 27% risk reduction). There was no statistical difference in risk observed between the non-adherent and partially adherent groups. Full adherence was associated with reduced per-patient annual direct medical costs associated with hospitalisations for MI of $369 and $440 and for revascularisations of $539 and $844 in partial adherence and non-adherence, respectively.
Data from European cohorts using absolute and relative risk assessments demonstrate that a considerable proportion of all CVD events (9% in Europe) could be attributed to poor adherence to vascular medications alone. 13 Furthermore, medication nonadherence carries a huge medical and economic burden. According to the Pharmaceutical Group of the European Union (PGEU), it has been estimated that there are 194,500 deaths a year in the European Union due to miss-dosing and non-adherence to prescribed medication, resulting in an estimated cost of E125b annually. 14 The issue is particularly relevant in wealthier nations, where access to and use of healthcare systems are high, and where further increasing the effectiveness of a medication could rely largely on improving adherence levels.
These data raise important questions about what actionable steps cardiologists, general practitioners, nurses and others who care for these patients should take in order to ensure patient adherence to prescribed regimens. Involving patients in the decision to prescribe medications, counselling and close patient monitoring in order to manage side effects improve adherence, but these interventions can be complicated and expensive, and are only part of the solution. Predictive models indicate that interventions that reduce patients' pill burdens, specifically the cardiovascular polypill for secondary prevention, when used in concert with other efforts show promise for improving adherence, and ultimately patient outcomes. 15 Evidence for the use of polypills in secondary cardiovascular prevention Evidence from 13 randomised controlled trial (RCTs) including more than 9000 participants in 32 countries is currently available on the efficacy, safety, tolerability, affordability and cost-effectiveness of a polypill strategy for the primary and secondary prevention of CVD and has been reviewed extensively elsewhere. [16] [17] [18] [19] [20] [21] Three important randomised clinical trials have recently tested the effect of polypill strategies on adherence. The Kanyini Guidelines adherence with the polypill (GAP), 22 Improving adherence using combination therapy (IMPACT) 23 Recently, using individual patient data from these studies, Webster et al. published the results of a prospective meta-analysis comparing the effectiveness of polypills with usual care in patients with CVD or who were at high risk of CVD. 25 The primary outcomes were self-reported adherence to combination therapy (antiplatelet, statins and two or more BP-lowering agents) and difference in mean systolic BP and lowdensity lipoprotein cholesterol (LDL-C) at 12 months. Analyses used random effects models. Among 3140 patients from Australia, England, India, Ireland, New Zealand and The Netherlands (75% male, mean age 62 years), the median follow-up was 15 months. At baseline, 84%, 87% and 61%, respectively, were taking a statin, an antiplatelet agent and at least two BP-lowering agents. The meta-analysis concluded that, at 12 months, the use of a polypill therapy significantly improved adherence, systolic BP and LDL-C in highrisk patients compared with usual care, especially among those who were undertreated at baseline (Figure 3) .
The Fixed Dose Combination Drug for Secondary Cardiovascular Prevention (FOCUS) study was the first to prove the benefits of a polypill strategy in a homogeneous secondary prevention population. 26 FOCUS consisted of a cross-sectional study (phase 1) of 2118 post-MI patients recruited in Argentina, Brazil, Italy, Paraguay and Spain, and it aimed to elucidate the factors that interfere with appropriate adherence to cardiovascular medications for secondary prevention after an acute MI. Additionally, 695 patients from phase 1 were randomised into a controlled clinical trial (phase 2) in order to test the effects of Trinomia Õ (a polypill containing aspirin 100 mg, simvastatin 40 mg and ramipril 2.5, 5 or 10 mg) compared with the three drugs given separately on adherence, BP and LDL-C, as well as safety and tolerability, over a period of 9 months of follow-up. The primary end-point in phase Kanyini GAP IMPACT UMPIRE IPD Metanalysis Figure 3 . Results from randomised controlled trials and IPD meta-analyses measuring changes in adherence when comparing the polypill with usual care. GAP: guidelines adherence with the polypill; IMPACT: improving adherence using combination therapy; UMPIRE: use of a multidrug pill in reducing cardiovascular Events; IPD: individual patient data.
2 was adherence to the treatment measured at the final visit by the self-reported Morisky-Green Adherence Questionnaire and pill count. The results of phase 1 showed a very low overall adherence rate of 45.5%, which was consistent with other studies. In a multivariable regression model, the risk of being non-adherent was associated with younger age, depression, being on a complex medication regimen, poorer health insurance coverage and a lower level of social support, with consistent findings shown across countries. In agreement with other clinical trials, compared with the three drugs given separately, the use of a polypill strategy met the primary end-point for adherence -increased self-reported and direct measured medication -for secondary prevention following an acute MI. No treatment differences were found at follow-up in terms of mean systolic BP, mean LDL-C levels, serious adverse events or death.
Cost-effectiveness of the use of the polypill in secondary cardiovascular prevention compared to usual care
It has been shown that multidrug regimens for the primary and secondary prevention of CVD are costeffective in all global regions except sub-Saharan Africa. 27 Recently, the results of two studies using data from the UK and Spain on the cost-effectiveness of a polypill strategy have been published. 28 ,29 A Markov model-based cost-effectiveness analysis informed by systematic reviews (which identified efficacy, utility and adherence data inputs) was used in order to evaluate the public health and economic benefits of adherence to a polypill (containing 100 mg aspirin, 20 mg atorvastatin and 2.5, 5 or 10 mg ramipril) for the secondary prevention of cardiovascular events. According to these studies, in the UK, a 10% uptake of the polypill was estimated to prevent 3260 cardiovascular events and 590 cardiovascular deaths over the course of a decade. 28 In Spain, the model showed that over a 10-year period, use of the cardiovascular polypill instead of its individual components simultaneously would avoid 46 nonfatal and 11 fatal cardiovascular events per 1000 patients treated. The polypill would also be a more effective and cheaper strategy. Probabilistic analysis of the base case found a 90.9% probability that the polypill would be a cost-effective strategy compared with multiple monotherapies at a willingness-to-pay of E30,000 per quality-adjusted life year. 28 The polypill appears to be a cost-effective strategy for preventing fatal and non-fatal cardiovascular events. With this evidence, a polypill strategy was included in the 2016 European Guidelines on CVD prevention for the first time. 30 Gaps in the evidence and future trials Several large, ongoing studies are testing the ability of different polypills to reduce the occurrence of new cardiovascular events in real-world practice. The Indian Polycap Study (TIPS-3) and Heart outcomes and prevention evaluation (HOPE-4) are currently underway and are testing different combination pills against placebo. TIPS-3 will evaluate a preparation of the Polycap without aspirin (either with the doses used in the first The Indian Polycap Study (TIPS) trial or enhanced doses based on the results of the TIPS-K trial) versus placebo over 5 years in 5000 individuals without CVD and with an estimated risk of major CVD of 1% per year in India and China. HOPE-4 is a community cluster RCT that will evaluate an evidence-based programme for CVD risk assessment, treatment and control involving simplified screening and treatment algorithms implemented by non-physician health workers coupled with lifestyle counselling and combination pill therapy. The initial risk factor phase of the study will assess BP and cholesterol changes in Colombia and Malaysia (50 communities), with plans to expand to 190 communities in eight countries in order to evaluate CVD events over 6 years.
To date, no large RCT has been conducted in order to study the effects of a polypill strategy on outcomes in a secondary prevention population. The Secondary Prevention of Cardiovascular Disease in the Elderly (SECURE) trial, funded by H2020, is currently ongoing, and aims to evaluate whether Trinomia Õ (a polypill containing aspirin, atorvastatin and ramipril) will reduce the rate of death from cardiovascular causes, non-fatal MI, stroke and hospitalisation requiring revascularisation compared to usual care in post-MI patients over 65 years of age. The study is in its recruiting phase and several European countries with different rates of adherence and cardiovascular events are participating, with there being more nearly 90 participating centres across Spain, Italy, France, Hungary, Poland, Germany and the Czech Republic. Through pharmacoeconomic measures, SECURE will also test whether the polypill is a cost-effective strategy in the prevention of CVD. Additionally, regional differences in terms of adherence rates, risk factor control and cardiovascular events will also be studied in order to aid the different stakeholders in making appropriate decisions that are specific for each region. The results of SECURE are expected to evaluate the clinical use of the polypill in cardiovascular prevention.
Conclusions
There is still a huge opportunity for improving primary and secondary prevention, particularly in LMICs.
Polypills include guideline-recommended treatments for secondary prevention, such as BP-lowering, cholesterol-lowering and antiplatelet drugs. Polypill strategies have been shown to be effective, safe and cost-effective in terms of increasing drug adherence and improving risk factor profiles. As a result of these findings, the use of polypills was included in the 2016 European Guidelines on CVD prevention in clinical practice. However, the implementation of the polypill as a useful approach in secondary prevention has been slow. The results of TIPS-3, HOPE-4 and SECURE will help to more clearly establish the role of polypills in improving outcomes in cardiovascular prevention.
Predictions for the progression of the CVD pandemic, especially in LMICs, are poor, yet the shift in perception of the utility of the polypill by various stakeholders has been slow, and barriers persist in the global implementation of this proven strategy. International scientific societies (e.g. the Spanish Cardiology Society together with various internal medicine and primary care societies in Spain, the Inter-American Society of Cardiology, the Mexican Society of Cardiology, the Argentinian Society of Cardiology, the Chilean Society of Cardiology and the European Society of Hypertension, to name but a few) either have issued or are in the process of issuing position statements on the clinical use of the polypill in their respective regions. In effect, scientific societies are playing the role of an interlocutor with local regulators and policy makers in order to approve the use of the polypill and to utilise it, together with other strategies of health promotion, so as to effectively halt the progression of CVD worldwide.
